Twist Bioscience (NASDAQ:TWST) Insider Sells $128,494.60 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 949 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $128,494.60. Following the completion of the sale, the insider directly owned 62,840 shares in the company, valued at approximately $8,508,536. This trade represents a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Friday, October 2nd, Dennis Cho sold 9,514 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total transaction of $1,797,004.32.
• On Monday, September 21st, Dennis Cho sold 348 shares of Twist Bioscience stock. The stock was sold at an average price of $165.49, for a total transaction of $57,590.52.
• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The stock was sold at an average price of $122.62, for a total transaction of $50,519.44.

Twist Bioscience Stock Down 15.5%

NASDAQ TWST traded down $22.05 on Thursday, hitting $120.53. 3,084,289 shares of the stock were exchanged, compared to its average volume of 1,763,809. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71. The company has a 50-day moving average price of $152.59 and a 200-day moving average price of $90.28. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The company has a market cap of $7.56 billion, a PE ratio of -54.29 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.33 earnings per share. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of TWST. BlackRock Inc. purchased a new stake in shares of Twist Bioscience in the second quarter valued at about $600,191,000. William Blair Investment Management LLC acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $223,722,000. Bank of America Corp DE acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $94,922,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Twist Bioscience during the 1st quarter worth approximately $22,563,000. Finally, Bank of New York Mellon Corp purchased a new stake in Twist Bioscience in the 2nd quarter valued at approximately $19,722,000.

Wall Street Analyst Weigh In

Several research firms recently commented on TWST. Barclays increased their target price on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. BWS Financial reaffirmed a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Piper Sandler upped their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Leerink Partners upped their price objective on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, TD Cowen increased their target price on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $153.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.